Literature DB >> 1551116

Roles of human liver cytochrome P4502C and 3A enzymes in the 3-hydroxylation of benzo(a)pyrene.

C H Yun1, T Shimada, F P Guengerich.   

Abstract

The major oxidation product of the classic polycyclic hydrocarbon carcinogen benzo(a)pyrene [B(a)P] is 3-hydroxy B(a)P. Numerous studies have been concerned with the measurement of B(a)P 3-hydroxylation activity in experimental animals and human tissues. Although human liver is the main site of this reaction, systematic studies had not been carried out to define the roles of individual cytochrome P-450 (P-450) enzymes involved. Purified human P4502C8 and P4503A4 showed appreciable catalytic activity; purified human P4501A2 and yeast recombinant (human) P4502C9 and P4502C10 had less activity. No B(a)P 3-hydroxylation activity was observed with purified human P4502A6, P4502D6, P45602E1, or P4502CMP. When microsomes prepared from different human liver samples were compared, B(a)P 3-hydroxylation activity was well correlated with nifedipine oxidation (a P4503A4 marker) but not markers of other P-450s, including tolbutamide hydroxylation (P4502C9 and 2C10), chlorzoxazone 6-hydroxylation (P4502E1), (S)-mephenytoin 4'-hydroxylation (P4502CMP), and coumarin 7-hydroxylation (P4502A6). In three of the liver microsomal samples with relatively high B(a)P 3-hydroxylation activity, immunoinhibition was observed with anti-P4503A greater than anti-P4502C (and no inhibition with several other antibodies). The selective chemical inhibitors gestodene and troleandomycin (P4503A enzymes) and sulfaphenazole (P4502C enzymes) reduced the B(a)P 3-hydroxylation activity of the more active microsomal preparations to rates seen in the preparations with low activity. This residual activity (and most of the activity in the low activity samples) was refractory to all of the chemical inhibitors and antibodies. The addition of 7,8-benzoflavone dramatically stimulated B(a)P 3-hydroxylation in all of the microsomal samples (and also stimulated purified P4503A4), arguing against an important role for P4501A1 or P4501A2. We conclude that roles of human P-450 enzymes for B(a)P 3-hydroxylation follow the order P4503A4 greater than or equal to P4502C8 greater than P4502C9/10 in human liver and that the other P-450s examined here do not have major roles. P4502C8 and P4502CMP (but not P4503A4) were found to activate B(a)P to products genotoxic in Salmonella typhimurium; this pathway would appear to involve products other than 3-hydroxy B(a)P and B(a)P 7,8-dihydrodiols.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1551116

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Cytochromes P450 are expressed in proliferating cells in Barrett's metaplasia.

Authors:  S J Hughes; M A Morse; C M Weghorst; H Kim; P B Watkins; F P Guengerich; M B Orringer; D G Beer
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

Review 2.  Contributions of human enzymes in carcinogen metabolism.

Authors:  Slobodan Rendic; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2012-05-10       Impact factor: 3.739

Review 3.  Human Family 1-4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2021-01-18       Impact factor: 5.153

4.  Discovery of a widespread metabolic pathway within and among phenolic xenobiotics.

Authors:  Pahriya Ashrap; Guomao Zheng; Yi Wan; Tong Li; Wenxin Hu; Wenjuan Li; Hong Zhang; Zhaobin Zhang; Jianying Hu
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-23       Impact factor: 11.205

Review 5.  Development and Uses of Offline and Web-Searchable Metabolism Databases - The Case of Benzo[a]pyrene.

Authors:  Slobodan P Rendic; Frederick P Guengerich
Journal:  Curr Drug Metab       Date:  2018       Impact factor: 3.731

6.  Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma.

Authors:  Andrew T Chan; Ann G Zauber; Meier Hsu; Aurora Breazna; David J Hunter; Rebecca B Rosenstein; Craig J Eagle; Ernest T Hawk; Monica M Bertagnolli
Journal:  Gastroenterology       Date:  2009-02-21       Impact factor: 22.682

7.  Is quinine a suitable probe to assess the hepatic drug-metabolizing enzyme CYP3A4?

Authors:  Sompon Wanwimolruk; Mary F Paine; Susan N Pusek; Paul B Watkins
Journal:  Br J Clin Pharmacol       Date:  2002-12       Impact factor: 4.335

Review 8.  Oral benzo[a]pyrene: understanding pharmacokinetics, detoxication, and consequences--Cyp1 knockout mouse lines as a paradigm.

Authors:  Daniel W Nebert; Zhanquan Shi; Marina Gálvez-Peralta; Shigeyuki Uno; Nadine Dragin
Journal:  Mol Pharmacol       Date:  2013-06-12       Impact factor: 4.436

9.  CYP2C9 variants increase risk of colorectal adenoma recurrence and modify associations with smoking but not aspirin treatment.

Authors:  Elizabeth L Barry; Elizabeth M Poole; John A Baron; Karen W Makar; Leila A Mott; Robert S Sandler; Dennis J Ahnen; Robert S Bresalier; Gail E McKeown-Eyssen; Cornelia M Ulrich
Journal:  Cancer Causes Control       Date:  2012-10-19       Impact factor: 2.506

10.  The inhibition of CYP enzymes in mouse and human liver by pilocarpine.

Authors:  T Kimonen; R O Juvonen; E Alhava; M Pasanen
Journal:  Br J Pharmacol       Date:  1995-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.